Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

Anthony A. Portale, Thomas O. Carpenter, Maria Luisa Brandi, Karine Briot, Hae Ii Cheong, Martine Cohen-Solal, Rachel Crowley, Suzanne Jan De Beur, Richard Eastell, Yasuo Imanishi, Erik A. Imel, Steven Ing, Nobuaki Ito, Muhammad Javaid, Peter Kamenicky, Richard Keen, Takuo Kubota, Robin Lachmann, Farzana Perwad, Pisit PitukcheewanontStuart H. Ralston, Yasuhiro Takeuchi, Hiroyuki Tanaka, Thomas J. Weber, Han Wook Yoo, Lin Zhang, Christina Theodore-Oklota, Matt Mealiffe, Javier San Martin, Karl Insogna

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period'. Together they form a unique fingerprint.

Medicine & Life Sciences